NCT00584519

Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight

Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight (CRESSOB)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 430 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To analyse the progress of modifiable metabolic risk factors (Blood pressure, cigarette smoking, waist perimeter, BMI, glycemia and lipidic profile) in schizophrenic patients with overweight for 12 months. To analyse the perceived health status and the level of functioning and disability of patients with schizophrenia and overweight and their progress at 3, 6 and 12 months. To assess the progress of the symptoms of the disease at 6 and 12 months.

Detailed description

Consecutive patient sampling. Any investigational site four consecutive patients with diagnosis of Schizophrenia (DSM-IV TR) and Overweight (BMI more or equal to 25 Kg/m2)

Conditions

• Schizophrenia

Interventions

Type	Name	Description
OTHER	non-interventional	non-interventional

Timeline

• Start date: 2007-06-01
• Primary completion: 2009-06-01
• Completion: 2009-06-01
• First posted: 2008-01-02
• Last updated: 2021-02-21